AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Description The purpose of this clinical practice update review is to describe key principles in the diagnosis and management of functional gastrointestinal (GI) symptoms in patients with inflammatory bowel disease (IBD). Methods The evidence and best practices summarized in this manuscript are based on relevant scientific publications, systematic reviews, and expert opinion where applicable. Best practice advice 1 A stepwise approach to rule-out ongoing inflammatory activity should be followed in IBD patients with persistent GI symptoms (measurement of fecal calprotectin, endoscopy with biopsy, cross-sectional imaging). Best practice advice 2 In those patients with indeterminate fecal calprotectin levels and mild symptoms, clinicians may consider serial calprotectin monitoring to facilitate anticipatory management. Best practice advice 3 Anatomic abnormalities or structural complications should be considered in patients with obstructive symptoms including abdominal distention, pain, nausea and vomiting, obstipation or constipation. Best practice advice 4 Alternative pathophysiologic mechanisms should be considered and evaluated (small intestinal bacterial overgrowth, bile acid diarrhea, carbohydrate intolerance, chronic pancreatitis) based on predominant symptom patterns. Best practice advice 5 A low FODMAP diet may be offered for management of functional GI symptoms in IBD with careful attention to nutritional adequacy. Best practice advice 6 Psychological therapies (cognitive behavioural therapy, hypnotherapy, mindfulness therapy) should be considered in IBD patients with functional symptoms. Best practice advice 7 Osmotic and stimulant laxative should be offered to IBD patients with chronic constipation. Best practice advice 8 Hypomotility agents or bile-acid sequestrants may be used for chronic diarrhea in quiescent IBD. Best practice advice 9 Antispasmodics, neuropathic-directed agents, and anti-depressants should be used for functional pain in IBD while use of opiates should be avoided. Best practice advice 10 Probiotics may be considered for treatment of functional symptoms in IBD. Best practice advice 11 Pelvic floor therapy should be offered to IBD patients with evidence of an underlying defecatory disorder. Best practice advice 12 Until further evidence is available, fecal microbiota transplant should not be offered for treatment of functional GI symptoms in IBD. Best practice advice 13 Physical exercise should be encourage in IBD patients with functional GI symptoms. Best practice advice 14 Until further evidence is available, complementary and alternative therapies should not be routinely offered for functional symptoms in IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial
Johannesson, E., Simrén, M., Strid, H., Bajor, A., & Sadik, R. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.480 · Cited by 431
Bi-directionality of brain–gut interactions in patients with inflammatory bowel disease
Gracie, D. J., Guthrie, E. A., Hamlin, P. J., & Ford, A. C. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.027 · Cited by 408
Chang, J., Leong, R. W., Wasinger, V. C., Ip, M., Yang, M., & Phan, T. G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.056 · Cited by 286
Oral bisacodyl is effective and well-tolerated in patients with chronic constipation
Kamm, M. A., Mueller–Lissner, S., Wald, A., Richter, E., Swallow, R., & Gessner, U. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.026 · Cited by 257
Simrén, M. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)04037-0 · Cited by 186
Chapman, R. W., Stanghellini, V, Geraint, M., & Halphen, M. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.197 · Cited by 180
Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits
Camilleri, M., Lembo, A., & Katzka, D. A. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.05.014 · Cited by 176
Psychological Interventions for Irritable Bowel Syndrome and Inflammatory Bowel Diseases
Ballou, S., & Keefer, L. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.69 · Cited by 167
Tricyclic Antidepressants for Management of Residual Symptoms in Inflammatory Bowel Disease
Iskandar, H. N., Cassell, B., Kanuri, N., Gyawali, C. P., Gutierrez, A., Dassopoulos, T., Ciorba, M. A., & Sayuk, G. S. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000049 · Cited by 96
Cited by
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Drewes, A. M., Olesen, A. E., Farmer, A. D., Szigethy, E., Rebours, V., & Olesen, S. S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0135-7 · Cited by 272
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Liu, S., Zhao, W., Lan, P., & Mou, X. (2021) · Protein & Cell · doi:10.1007/s13238-020-00745-3 · Cited by 263
Metadata
- Authors
- Colombel, J.-F., Shin, A., & Gibson, P. R.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 17
- Issue
- 3
- Pages
- 380-390.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2886250794
- Cited by
- 203
- References
- 13
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.